Recent advances of HIF-2α in pulmonary hypertension
10.16438/j.0513-4870.2021-0632
- VernacularTitle:HIF-2α在肺动脉高压中的研究进展
- Author:
Lei JI
1
;
Zhan-qiang LI
2
;
Dian-xiang LU
2
Author Information
1. Research Center for High Altitude Medicine, Qinghai University, Xining 810001, China; Key Laboratory of High Altitude Medicine (Ministry of Education), Key Laboratory of Application and Foundation for High Altitude Medicine Research in Qinghai Province (Qinghai-Utah Joint Research Key Lab for High Altitude Medicine), Xining 810001, China; Qinghai Provincial People's Hospital, Xining 810007, China
2. Research Center for High Altitude Medicine, Qinghai University, Xining 810001, China; Key Laboratory of High Altitude Medicine (Ministry of Education), Key Laboratory of Application and Foundation for High Altitude Medicine Research in Qinghai Province (Qinghai-Utah Joint Research Key Lab for High Altitude Medicine), Xining 810001, China
- Publication Type:Research Article
- Keywords:
hypoxic inducible factor-2α;
pulmonary hypertension;
endothelial cell;
hypoxic inducible factor-1α;
treatment
- From:
Acta Pharmaceutica Sinica
2022;57(2):277-286
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary hypertension (PH) is a kind of disease characterized by progressive increase of pulmonary vascular resistance and occlusive vascular remodeling. Hypoxic inductive factor-2α (HIF-2α) plays an important role in the abnormal proliferation of pulmonary vascular cells and pulmonary vascular remodeling. This review focuses on the role of HIF-2α in pulmonary hypertension at the cellular and the global level, and candidates targeting HIF-2α for the treatment of pulmonary hypertension, in order to better understand the pathogenesis of PH and find effective treatments.
